Arcutis Biotherapeutics, Inc.
ARQTHealthcareNASDAQBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframeArcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Valued at $2.68B, ARQT is a mid-cap name in its sector. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
Market Cap
$2.68B
Beta
1.59
P/E (TTM)
—
P/E (Fwd)
18.57
EPS (TTM)
$-0.02
EPS (Fwd)
$1.16
ROE
-1.4%
ROA
0.5%
Cash
$224.0M
Total Debt
$114.7M
Free CF
$3.5M
52W Change
59.2%
Annual Financials
Cash vs Debt
Arcutis Biotherapeutics, Inc. holds $224.0M in cash against $114.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $3.5M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -1.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 0.5% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $3.7M (2022) to $376.1M (2025), reflecting a 10103% increase over the period.
With a beta above 1.5, ARQT tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Arcutis Biotherapeutics, Inc. and its sector.